KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup Analysis.

Masato Takahashi, Hirofumi Mukai, Toshimi Takano, Koichiro Tsugawa, Kenichi Inoue, Mitsuya Itoh, Junichiro Watanabe, Yuko Tanabe, Naohito Yamamoto, Yasuo Miyoshi, Kenichi Watanabe, Toru Mukohara, Yibin Kong, Masashi Shimura, Francisco Beca, Peter Schmid, Hiroji Iwata

Cancer Sci 117(4) 1106-1116

PMID41536071
PMCIDPMC13045266
DOI10.1111/cas.70307
发表日期2026-01-15
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

The phase 3 KEYNOTE-522 study in high-risk early-stage triple-negative breast cancer (TNBC) showed significantly improved efficacy outcomes with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab versus neoadjuvant chemotherapy alone. We present findings from the KEYNOTE-522 Japan subgroup. Eligible participants (aged ≥ 18 years) with untreated locally advanced TNBC (stage T1c N1-2 or T2-4 N0-2) were randomized 2:1 to neoadjuvant pembrolizumab 200 mg or placebo plus chemotherapy every 3 weeks for 8 cycles followed by surgery and adjuvant pembrolizumab or placebo for ≤ 9 cycles. Primary endpoints were pathologic complete response (pCR; ypT0/Tis ypN0) at the time of surgery and event-free survival (EFS). Of 76 participants enrolled in Japan, 45 were randomized to the pembrolizumab arm and 31 to the placebo arm. Median time from randomization to data cutoff (March 22, 2024) was 76.3 months. Twenty-four participants (53%) in the pembrolizumab arm and 15 (48%) in the placebo arm achieved pCR (between-treatment arm difference, 4.9%; 95% CI, -17.6% to 27.1%); findings were similar regardless of PD-L1 expression. Rates of EFS at 60 months were 84% and 73%, respectively (HR, 0.54; 95% CI, 0.20-1.50). Grade 3 or 4 treatment-related AEs occurred in 37 of 45 participants (82%) treated with pembrolizumab and 23 of 30 participants (77%) treated with placebo; there were no grade 5 AEs. In conclusion, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab showed improved efficacy outcomes and manageable safety versus neoadjuvant chemotherapy alone in Japanese participants, supporting the use of this regimen in Japanese patients with high-risk early-stage TNBC. Trial Registration: The study (ClinicalTrials.gov, NCT03036488) was conducted in compliance with local and/or national regulations and International Council for Harmonization Good Clinical Practice guidelines and in accordance with the ethical principles originating from the Declaration of Helsinki.

KM 提取结果

2 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure2 个面板

FIGURE 2

FIGURE 2 Kaplan–Meier estimates of EFS (A) in the overall population and (B) by pCR status. EFS, event‐free survival; pCR, pathologic complete response.

A

EFS

FIGURE 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

EFS

FIGURE 2 · Panel B

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel B 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure2 个面板

FIGURE 3

FIGURE 3 Kaplan–Meier estimates of OS (A) in the overall population and (B) by pCR status. OS, overall survival; pCR, pathologic complete response.

A

OS

FIGURE 3 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

OS by pCR status

FIGURE 3 · Panel B

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel B 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 4:extreme upward reversal
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 pCR (ypT0/Tis ypN0) (A) in the overall population and (B) by PD‐L1 CPS. CPS, combined positive score; pCR, pathologic complete response; PD‐L1, programmed cell death ligand 1.
非 KM Figure